EXACTUS, INC. (OTCMKTS:EXDI) Files An 8-K Unregistered Sales of Equity Securities

EXACTUS, INC. (OTCMKTS:EXDI) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities.

Story continues below

On February 28, 2019, we held additional closings in our private placement offering of common stock, par value $0.0001 per share (the “Common Stock”). As disclosed in our Current Report on Form 8-K filed February 21, 2019, we have previously accepted subscriptions of $1,154,500 for a total of 46,180,000 shares of Common Stock. The additional closings held February 28, 2019 were for an additional $679,553 for an additional 25,118,628 shares of Common Stock. In total, we have accepted subscriptions in the amount of $1,834,053 for a total of 71,298,628 shares of Common Stock. The offer and sale of these shares was made solely to “Accredited Investors” as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933 (the “Securities Act”). We engaged in no general solicitation or advertising with regard to the offering. Accordingly, the offer and sale of these shares was exempt under Rule 506 of Regulation D under the Securities Act.

Following the issuance of common stock as described above, our total issued and outstanding common stock will be 195,315,832 shares.

Section 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits

Exhibit No.

Description

10.1

Form of Subscription Agreement for Common Stock(1)

(1) Incorporated by reference to Current Report on Form 8-K filed February 21, 2019.

About EXACTUS, INC. (OTCMKTS:EXDI)

Exactus, Inc. (Exactus), formerly Spiral Energy Tech, Inc., is a life science company. The Company will develop and commercialize Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a detection platform. The Company’s primary business focus will be the development and commercialization of the FibriLyzer and related technology licensed by Exactus. The Company’s products will employ a disposable test biosensor strip combined with a portable hand held detection unit that provides a result in approximately 30 seconds. The Company intends to file to gain regulatory approval and launch its products in the United States and Europe.

An ad to help with our costs